Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
Rhea-AI Summary
Moleculin (Nasdaq: MBRX) announced that CEO Walter Klemp appeared in a Virtual Investor “What This Means” segment.
He discussed reaching enrollment of the 45th subject in the pivotal Phase 2B/3 MIRACLE trial of Annamycin plus cytarabine (AnnAraC) in adult R/R AML, and preparations for interim data unblinding targeted for mid-2026.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – MBRX
On the day this news was published, MBRX gained 2.03%, reflecting a moderate positive market reaction. This price movement added approximately $280K to the company's valuation, bringing the market cap to $14.08M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed moves, with names like LPTX up 238.84% while others such as KZIA, INTS, MBIO, and SNGX are down between low- and high-single digits. With MBRX flat on the day, this points to stock-specific dynamics rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 29 | ASCO safety data | Positive | +1.8% | ASCO 2026 data showing no detectable cardiotoxicity across five Annamycin trials. |
| May 21 | ASCO poster acceptance | Positive | +0.0% | Acceptance of pooled Annamycin cardiac safety data for ASCO 2026 poster presentation. |
| May 15 | Q1 2026 earnings | Neutral | -4.1% | Q1 2026 results with MIRACLE update, higher R&D, financing and cash runway disclosure. |
| May 13 | MIRACLE efficacy update | Positive | -8.6% | Blinded MIRACLE data showing CRc >40% and CR ~30% vs historical cytarabine benchmarks. |
| May 12 | Cardiac safety update | Positive | -4.1% | Cleveland Clinic review finding no clinically significant cardiotoxicity in R/R AML patients. |
Recent news skewed positive around Annamycin safety and MIRACLE progress, yet share reactions often leaned flat to negative, indicating a tendency for the stock to fade upbeat clinical and trial updates.
Over the past months, Moleculin has focused on advancing Annamycin and its pivotal MIRACLE Phase 2B/3 trial in relapsed/refractory AML. Multiple updates in April–May 2026 emphasized favorable cardiac safety data across 90 treated patients, encouraging blinded response rates, and patent extensions. Q1 2026 results highlighted rising R&D spend and financing needs alongside MIRACLE enrollment progress. Today’s announcement that the 45th subject has been enrolled and that interim unblinding preparation has begun fits into this steady drumbeat of trial execution milestones.
Regulatory & Risk Context
An effective S-3 filing dated March 27, 2026 registers up to 6,367,956 shares issuable upon exercise of February 2026 warrants. The warrants have a $2.3976 exercise price and a beneficial ownership cap of 4.99% or 9.99%, with full cash exercise corresponding to $15.3 million in gross proceeds. This structure enables potential resale of warrant shares once exercised.
Market Pulse Summary
This announcement highlights that Moleculin’s pivotal MIRACLE trial has enrolled its 45th subject, initiating the final preparations for interim data unblinding targeted for mid-2026. It builds on recent disclosures of encouraging blinded response rates and favorable cardiac safety for Annamycin. At the same time, recent filings describe higher R&D spending, limited cash extending only into the third quarter of 2026, and an effective S-3 registering warrant shares, underscoring that both clinical outcomes and financing developments remain key metrics to watch.
Key Terms
pivotal phase 2b/3 medical
cytarabine medical
annamycin medical
acute myeloid leukemia medical
relapsed or refractory medical
r/r aml medical
data unblinding technical
AI-generated analysis. Not financial advice.
- Access the segment here
HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor “What This Means” segment.
As part of the segment, Mr. Klemp discussed the Company’s recent news announcing that the 45th subject has been enrolled in its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adult subjects with relapsed or refractory acute myeloid leukemia (R/R AML). Mr. Klemp gave insight into how this milestone triggers the final phase of preparation for the trial’s interim 45 subject data unblinding, which remains on track for mid-2026 and represents a potentially defining inflection point for the Company.
The segment is now available for on-demand viewing here.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the expected timing and results of the 45-subject interim data unblinding in the MIRACLE trial, the anticipated clinical milestones set forth above, and the potential efficacy and safety of Annamycin and AnnAraC in R/R AML and other indications. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
